Article thumbnail

Targeting metabolism with arsenic trioxide and dichloroacetate in breast cancer cells

By Ramon C Sun, Philip G Board and Anneke C Blackburn
Topics: Research
Publisher: BioMed Central
OAI identifier:
Provided by: PubMed Central

Suggested articles


  1. (2007). A: Targeting thioredoxin reductase is a basis for cancer therapy by arsenic trioxide.
  2. (2010). AC: Reversal of the glycolytic phenotype by dichloroacetate inhibits metastatic breast cancer cell growth in vitro and in vivo. Breast Cancer Res Treat
  3. (2008). Acute promyelocytic leukemia: from highly fatal to highly curable. Blood
  4. (2006). AD: Mechanism of opening of mitochondrial permeability transition pore induced by arsenic trioxide. Ai Zheng
  5. (2003). Akao Y: Antitumor effect of arsenic trioxide in murine xenograft model. Cancer Sci
  6. (2010). al: A phase I study of 5-fluorouracil/leucovorin and arsenic trioxide for patients with refractory/relapsed colorectal carcinoma. Clin Cancer Res
  7. (2007). Ardalan B: Arsenic trioxide/ascorbic acid therapy in patients with refractory metastatic colorectal carcinoma: a clinical experience. Acta Oncol
  8. (2001). Arner ESJ: Reactive oxygen species, antioxidants, and the mammalian thioredoxin system. Free Radical Biology and Medicine
  9. (2008). Arsenic trioxide mechanisms of action–looking beyond acute promyelocytic leukemia. Leuk Lymphoma
  10. (2002). Arsenic trioxide-induced apoptosis through oxidative stress in cells of colon cancer cell lines. Life Sciences
  11. (2008). Arsenic-based antineoplastic drugs and their mechanisms of action. Met Based Drugs
  12. (1998). Bax and adenine nucleotide translocator cooperate in the mitochondrial control of apoptosis. Science
  13. (2005). C: A phase II trial of arsenic trioxide in patients with metastatic melanoma. Cancer
  14. (2007). CB: Beyond aerobic glycolysis: Transformed cells can engage in glutamine metabolism that exceeds the requirement for protein and nucleotide synthesis. Proc Natl Acad Sci
  15. (2008). CJ: Dichloroacetate (DCA) sensitizes both wild-type and over expressing Bcl-2 prostate cancer cells in vitro to radiation. Prostate
  16. (2004). Cuezva JM: Alteration of the bioenergetic phenotype of mitochondria is a hallmark of breast, gastric, lung and oesophageal cancer.
  17. (2010). Cuezva JM: Selection of cancer cells with repressed mitochondria triggers colon cancer progression. Carcinogenesis
  18. (1997). Dang CV: c-Myc transactivation of LDH-A: Implications for tumor metabolism and growth. Proc Natl Acad Sci USA
  19. (2006). Dang CV: Cancer’s molecular sweet tooth and the Warburg effect. Cancer Res
  20. (2008). De Vivo I: Dichloroacetate induces apoptosis in endometrial cancer cells. Gynecol Oncol
  21. (2011). Denko NC: Anticancer drugs that target metabolism: Is dichloroacetate the new paradigm?
  22. (2009). Denko NC: Oxygen consumption can regulate the growth of tumors, a new perspective on the Warburg effect. PLoS One
  23. (2010). DL: Sodium Dichloroacetate (DCA) selectively targets cells with defects in the mitochondrial ETC.
  24. (2007). et al: A mitochondria-K+ channel axis is suppressed in cancer and its normalization promotes apoptosis and inhibits cancer growth. Cancer Cell
  25. (2010). et al: Arsenic trioxide improves event-free and overall survival for adults with acute promyelocytic leukemia: North American Leukemia Intergroup Study C9710. Blood
  26. (2000). et al: Arsenic trioxide-induced apoptosis and differentiation are associated respectively with mitochondrial transmembrane potential collapse and retinoic acid signaling pathways in acute promyelocytic leukemia. Leukemia
  27. (2010). et al: Metabolic modulation of glioblastoma with dichloroacetate. Sci Transl Med
  28. (1997). et al: Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood
  29. (1999). G: Arsenite induces apoptosis via a direct effect on the mitochondrial permeability transition pore. Exp Cell Res
  30. (2002). Generation of reactive oxygen species by the mitochondrial electron transport chain.
  31. (2003). Germano I: Induction of autophagic cell death in malignant glioma cells by arsenic trioxide. Cancer Res
  32. (1999). Glutathione and glutathione-dependent enzymes represent a co-ordinately regulated defence against oxidative stress. Free Radic Res
  33. (2007). Hogg PJ: Arsenical-based cancer drugs. Cancer Treat Rev
  34. (2002). Holbrook NJ: Cellular response to oxidative stress: Signaling for suicide and survival.
  35. (2005). Huang X: mCICR is required for As2O3-induced permeability transition pore opening and cytochrome c release from mitochondria. Mol Cell Biochem
  36. (2001). Introduction: the history of arsenic trioxide in cancer therapy. Oncologist
  37. (2001). Kakizuka A: Tumor Growth Inhibition by Arsenic Trioxide (As2O3) in the Orthotopic Metastasis Model of Androgen-independent Prostate Cancer. Cancer Res
  38. (2000). KN: Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L). Blood
  39. (1993). Lightowlers RN: A microtiter plate assay for cytochrome c oxidase in permeabilized whole cells. Analytical Biochemistry
  40. (1998). Mitochondria as regulators of apoptosis: Doubt no more. Biochimica et Biophysica Acta - Bioenergetics
  41. (1926). Negelein E: Ueber den Stoffwechsel von Tumoren im körper. Klinische Wochenschrift
  42. (2009). PG: Phenylalanine-induced leucopenia in genetic and dichloroacetic acid generated deficiency of glutathione transferase Zeta. Biochem Pharmacol
  43. (2004). Q: Essential role of the voltage-dependent anion channel (VDAC) in mitochondrial permeability transition pore opening and cytochrome c release induced by arsenic trioxide. Oncogene
  44. (2003). Reactive oxygen species are involved in arsenic trioxide inhibition of pyruvate dehydrogenase activity. Chem Res Toxicol
  45. (1999). Redox regulation of cellular signalling. Cellular Signalling
  46. (2009). Regulation of cancer cell metabolism by hypoxia-inducible factor 1. Semin Cancer Biol
  47. (2004). ROS stress in cancer cells and therapeutic implications. Drug Resist Updat
  48. (1996). S: The whole structure of the 13-subunit oxidized cytochrome c oxidase at 2.8 A. Science
  49. (2010). SD: Arsenic trioxide - An old drug rediscovered. Blood Rev
  50. (2004). SX: Effect of arsenic trioxide on human hepatocarcinoma in nude mice.
  51. (2006). The c-Myc target gene network. Seminars in Cancer Biology
  52. (2007). YC: Survivin mediates the antiapoptotic effect of δ-opioid receptor stimulation in cardiomyocytes.

To submit an update or takedown request for this paper, please submit an Update/Correction/Removal Request.